{"id":579610,"date":"2021-12-20T11:30:01","date_gmt":"2021-12-20T11:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=579610"},"modified":"2021-12-20T11:30:01","modified_gmt":"2021-12-20T11:30:01","slug":"aspergillosis-market-analysis-insights-into-epidemiology-segmentation-treatment-landscape-pipeline-therapies-and-key-companies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/aspergillosis-market-analysis-insights-into-epidemiology-segmentation-treatment-landscape-pipeline-therapies-and-key-companies_579610.html","title":{"rendered":"Aspergillosis Market Analysis: Insights into Epidemiology Segmentation, Treatment Landscape, Pipeline Therapies, and Key Companies"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1639973203.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Aspergillosis Market Analysis: Insights into Epidemiology Segmentation, Treatment Landscape, Pipeline Therapies, and Key Companies\" src=\"https:\/\/www.abnewswire.com\/uploads\/1639973203.png\" alt=\"Aspergillosis Market Analysis: Insights into Epidemiology Segmentation, Treatment Landscape, Pipeline Therapies, and Key Companies\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Aspergillosis Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Several approved therapies are driving the current Aspergillosis therapeutic landscape in the United States.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/aspergillosis-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Aspergillosis market report<\/a><\/strong> offers comprehensive coverage of the current treatment practices, pipeline therapies, and market share of the individual drug, current and forecasted Aspergillosis market size from 2018 to 2030 in the 7MM.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Aspergillosis Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>As per DelveInsight estimates, three Major Subtypes (ABPA, IA, and CPA) prevalent population was found to be <strong>555,840<\/strong> in the US in 2020.<\/li>\n<li>The diagnosed and treated cases of <strong>ABPA<\/strong> were highest in the US, followed by <strong>IA and CPA<\/strong> in 2020.<\/li>\n<li>Among the EU5 countries, the <strong>UK<\/strong> had the highest diagnosed and treated Aspergillosis cases in 2020.<\/li>\n<li>Leading companies in the Aspergillosis market include <strong>F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, Pulmocide, Sanofi,<\/strong> and others.<\/li>\n<li>Key Aspergillosis therapies in the pipeline include <strong>Olorofim, Pulmazole, Voriconazole dry-powder inhalation (TFF-VORI), Ibrexafungerp, PC945, Dupilumab,<\/strong> and others.&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Request for Aspergillosis market report sample to understand more about the emerging drug landscape @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/aspergillosis-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Aspergillosis Market Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Aspergillosis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Aspergillosis is an infection or allergic reaction caused by the fungus Aspergillus, common in the environment. The most common types of aspergillosis are chronic pulmonary aspergillosis (CPA), invasive aspergillosis (IA), and allergic bronchopulmonary aspergillosis (ABPA).<\/p>\n<p style=\"text-align: justify;\"><strong>Aspergillosis Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\">The Aspergillosis report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Aspergillosis Prevalent Cases&nbsp;<\/li>\n<li>Aspergillosis Diagnosed and Treated Cases<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Aspergillosis Treatment Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\">Antifungal medications, such as <strong>Azoles, Echinocandins, and Amphotericin B,<\/strong> are currently the most commonly used treatment modality for Aspergillosis. Several triazoles, including <strong>voriconazole and isavuconazole,<\/strong> are also used&nbsp; to treat invasive aspergillosis.<\/p>\n<p style=\"text-align: justify;\"><strong>Aspergillosis Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\">Several approved therapies are driving the current Aspergillosis therapeutic landscape in the United States. The launch of the most anticipated therapies such as <strong>Ibrexafungerp, PC945, Dupilumab,<\/strong> and others, which are expected to show changes in the current Aspergillosis market, is the primary reason for the market upsurge.<\/p>\n<p style=\"text-align: justify;\">Discover more about the future market share of the drugs @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/aspergillosis-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Aspergillosis Market Share<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Aspergillosis Pipeline Therapies and Key Companies<\/strong>&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Olorofim: F2G&nbsp;<\/li>\n<li>Pulmazole (PUR1900): Pulmatrix<\/li>\n<li>Voriconazole dry-powder inhalation (TFF-VORI): TFF Pharmaceuticals<\/li>\n<li>Ibrexafungerp: Scynexis<\/li>\n<li>PC945: Pulmocide<\/li>\n<li>Dupilumab: Sanofi<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<table border=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td>\n<p>1.<\/p>\n<\/td>\n<td>\n<p>Key Insights<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>2.<\/p>\n<\/td>\n<td>\n<p>Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>3.<\/p>\n<\/td>\n<td>\n<p>SWOT Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>4.<\/p>\n<\/td>\n<td>\n<p>Aspergillosis Market Overview at a Glance<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>5.<\/p>\n<\/td>\n<td>\n<p>Disease Background and Overview: Aspergillosis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>6.<\/p>\n<\/td>\n<td>\n<p>Recognized Establishments<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>7.<\/p>\n<\/td>\n<td>\n<p>Epidemiology and Patient Population<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>8.<\/p>\n<\/td>\n<td>\n<p>Country Wise-Epidemiology of Aspergillosis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>9.<\/p>\n<\/td>\n<td>\n<p>Treatment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>10.<\/p>\n<\/td>\n<td>\n<p>Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>11.<\/p>\n<\/td>\n<td>\n<p>Marketed Drugs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>12.<\/p>\n<\/td>\n<td>\n<p>Emerging Drugs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>13.<\/p>\n<\/td>\n<td>\n<p>Aspergillosis: 7 Major Market Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>14.<\/p>\n<\/td>\n<td>\n<p>Market Outlook&nbsp;<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>15.<\/p>\n<\/td>\n<td>\n<p>Patient Journey<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>16.<\/p>\n<\/td>\n<td>\n<p>Market Drivers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>17.<\/p>\n<\/td>\n<td>\n<p>Market Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>18.<\/p>\n<\/td>\n<td>\n<p>Access and Reimbursement<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>19.<\/p>\n<\/td>\n<td>\n<p>Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>20.<\/p>\n<\/td>\n<td>\n<p>DelveInsight Capabilities<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>21.<\/p>\n<\/td>\n<td>\n<p>Disclaimer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>22.<\/p>\n<\/td>\n<td>\n<p>About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">Get in touch with our business executive for <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Healthcare Due Diligence Services<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/invasive-aspergillosis-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Invasive Aspergillosis Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s <strong>&#8220;Invasive Aspergillosis- Market Insights, Epidemiology, and Market Forecast-2030&#8221;<\/strong> report delivers an in-depth understanding of the Invasive Aspergillosis, historical and forecasted epidemiology as well as the Invasive Aspergillosis market trends in the 7MM.<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=aspergillosis-market-analysis-insights-into-epidemiology-segmentation-treatment-landscape-pipeline-therapies-and-key-companies\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=aspergillosis-market-analysis-insights-into-epidemiology-segmentation-treatment-landscape-pipeline-therapies-and-key-companies\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aspergillosis Market Several approved therapies are driving the current Aspergillosis therapeutic landscape in the United States. DelveInsight&rsquo;s Aspergillosis market report offers comprehensive coverage of the current treatment practices, pipeline therapies, and market share of the individual drug, current and forecasted &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/aspergillosis-market-analysis-insights-into-epidemiology-segmentation-treatment-landscape-pipeline-therapies-and-key-companies_579610.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-579610","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/579610","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=579610"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/579610\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=579610"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=579610"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=579610"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}